These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15215150)

  • 1. Pharmacokinetics of oral valganciclovir and intravenous ganciclovir administered to prevent cytomegalovirus disease in an adult patient receiving small-intestine transplantation.
    Fortún Abete J; Martín-Dávila P; Moreno S; Quijano Y; de Vicente E; Pou L
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2782-3. PubMed ID: 15215150
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients.
    Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J
    Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
    Brown F; Banken L; Saywell K; Arum I
    Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of valganciclovir pharmacokinetics in lung transplant recipients.
    Kiser TH; Fish DN; Zamora MR
    J Heart Lung Transplant; 2012 Feb; 31(2):159-66. PubMed ID: 22305377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl.
    Burri M; Wiltshire H; Kahlert C; Wouters G; Rudin C
    Pediatr Infect Dis J; 2004 Mar; 23(3):263-6. PubMed ID: 15014306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation.
    Acosta EP; Brundage RC; King JR; Sánchez PJ; Sood S; Agrawal V; Homans J; Jacobs RF; Lang D; Romero JR; Griffin J; Cloud G; Whitley R; Kimberlin DW;
    Clin Pharmacol Ther; 2007 Jun; 81(6):867-72. PubMed ID: 17392728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.
    Razonable RR; Paya CV
    Expert Rev Anti Infect Ther; 2004 Feb; 2(1):27-41. PubMed ID: 15482169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients.
    Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N;
    Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract.
    Winston DJ; Baden LR; Gabriel DA; Emmanouilides C; Shaw LM; Lange WR; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2006 Jun; 12(6):635-40. PubMed ID: 16737936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic profile of valganciclovir in pediatric transplant recipients.
    Launay E; Théôret Y; Litalien C; Duval M; Alvarez F; Lapeyraque AL; Phan V; Larocque D; Poirier N; Lamarre V; Ovetchkine P
    Pediatr Infect Dis J; 2012 Apr; 31(4):405-7. PubMed ID: 22198827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
    Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
    Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.
    Caldés A; Colom H; Armendariz Y; Garrido MJ; Troconiz IF; Gil-Vernet S; Lloberas N; Pou L; Peraire C; Grinyó JM
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4816-24. PubMed ID: 19738014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
    Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection.
    Stockmann C; Roberts JK; Knackstedt ED; Spigarelli MG; Sherwin CM
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):205-19. PubMed ID: 25428442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Valganciclovir. Oral treatment of Cytomegalovirus infections].
    Kroes AC
    Ned Tijdschr Geneeskd; 2004 Jun; 148(25):1236-8. PubMed ID: 15301386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of Population Pharmacokinetics to Dose Optimization of Ganciclovir-Valganciclovir in Solid-Organ Transplant Patients.
    Padullés A; Colom H; Bestard O; Melilli E; Sabé N; Rigo R; Niubó J; Torras J; Lladó L; Manito N; Caldés A; Cruzado JM; Grinyó JM; Lloberas N
    Antimicrob Agents Chemother; 2016 Apr; 60(4):1992-2002. PubMed ID: 26824942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
    Martin DF; Sierra-Madero J; Walmsley S; Wolitz RA; Macey K; Georgiou P; Robinson CA; Stempien MJ;
    N Engl J Med; 2002 Apr; 346(15):1119-26. PubMed ID: 11948271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics.
    Filler G; Lampe D; von Bredow MA; Lappenberg-Pelzer M; Rocher S; Strehlau J; Ehrich JH
    Pediatr Nephrol; 1998 Jan; 12(1):6-9. PubMed ID: 9502557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir.
    Mattes FM; Hainsworth EG; Hassan-Walker AF; Burroughs AK; Sweny P; Griffiths PD; Emery VC
    J Infect Dis; 2005 Jan; 191(1):89-92. PubMed ID: 15593008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.